ABSTRACT

Purpose: This study aimed to investigate the relationship between clinical and laboratory parameters and complication status to predict which patients can be safely discharged from the hospital on the third postoperative day (POD).

Materials and Methods: Data from a prospectively maintained database of 2,110 consecutive patients with gastric adenocarcinoma who underwent curative surgery were reviewed. The third POD vital signs, laboratory data, and details of the course after surgery were collected. Patients with grade II or higher complications after the third POD were considered unsuitable for early discharge. The performance metrics were calculated for all algorithm parameters. The proposed algorithm was tested using a validation dataset of consecutive patients from the same center.

Results: Of 1,438 patients in the study cohort, 142 (9.9%) were considered unsuitable for early discharge. C-reactive protein level, body temperature, pulse rate, and neutrophil count had good performance metrics and were determined to be independent prognostic factors. An algorithm consisting of these 4 parameters had a negative predictive value (NPV) of 95.9% (95% confidence interval [CI], 94.2–97.3), sensitivity of 80.3% (95% CI, 72.8–86.5), and specificity of 51.1% (95% CI, 48.3–53.8). Only 28 (1.9%) patients in the study cohort were classified as false negatives. In the validation dataset, the NPV was 93.7%, sensitivity was 66%, and 3.3% (17/512) of patients were classified as false negatives.

Conclusions: Simple clinical and laboratory parameters obtained on the third POD can be used when making decisions regarding the safe early discharge of patients who underwent gastrectomy.

Keywords: Gastric cancer; Gastrectomy; Postoperative complications; Discharge; Readmission

INTRODUCTION

Gastric cancer surgery is a high-risk procedure associated with high surgical stress responses and potential risk for morbidity and mortality [1-5]. Postoperative complications may necessitate weeks of hospital stay, which is longer than that required for conventional gastrointestinal surgery. However, with the implementation of enhanced recovery after
surgery programs and minimally invasive surgical techniques, including laparoscopy and robotic surgery, the length of hospital stay has been shortened to 4–6 days [5-8]. Moreover, we recently demonstrated that hospital stays can be shortened to as few as 3–4 days [9]. These improvements have led to the question of how discharge decisions can be safely made in the early postoperative period.

During the past decade, attempts have been made to define safe early discharge criteria for patients [10-12]. Although several studies aimed to predict the “presence of complications,” few studies were able to predict the “absence of complications,” which is a critical component of safe discharge [13,14]. Studies attempting to determine the absence of complications have mainly investigated inflammatory parameters such as C-reactive protein (CRP) and procalcitonin as decisive markers [14,15]. Some studies have also integrated disease-specific laboratory markers or clinical parameters, including bowel function and pain scores, into the decision-making process [10-12].

Similar efforts have been made for gastric cancer surgery, with several approaches aimed at making a discharge decision on postoperative day (POD) 3–5 [14,16-18]. However, because some algorithms use combinations of clinical and laboratory values, complex calculation procedures are required for decision making. In addition, some algorithms require special tests (e.g., procalcitonin) that are not routinely used in clinical practice.

We hypothesized that safe early discharge criteria after gastric cancer surgery could be developed using simple and routinely used parameters obtained on POD 3. To test this hypothesis, we investigated the relationship between POD 3 clinical and laboratory parameters and delayed complication status to predict which patients could be safely discharged from the hospital.

MATERIALS AND METHODS

Data from a prospectively maintained database of 2,110 consecutive patients with gastric adenocarcinoma who underwent surgery by a single surgeon at Severance Hospital, Yonsei University Health System (Seoul, Korea) between March 2009 and April 2021 were retrospectively reviewed for the study cohort. Data for patients treated by other surgeons at the same hospital between January 1, 2015 and December 31, 2015, were reviewed for the validation cohort. Patients were excluded if they had the following: metastatic or an undetermined stage of disease, non-curative surgery, other organ malignancies, neoadjuvant treatment, remnant gastric cancers, American Society of Anesthesiologists (ASA) physical status score of IV, missing data for important postoperative parameters, cardiac arrhythmia, history of transplantation, Clavien-Dindo grade III or higher complications before or on the decision day (i.e., 3 days after surgery), or unresolved grade II or higher complications within 3 days after surgery. If a patient experienced grade II complications within 3 days after surgery that resolved before the decision day without further complications, the patient was considered to have no delayed complications. This study was approved by the institutional review board of Severance Hospital (4-2021-1708).

Clinical data, pathologic characteristics according to the 8th edition of the American Joint Committee on Cancer staging system, operative details following Korean and Japanese guidelines, and postoperative data, including laboratory/clincial data and complications
classified using the Clavien-Dindo system, were extracted from the database [19-22]. Adverse events occurring within 30 days after surgery (or within the hospitalization period for patients whose hospital stay was >30 days) were considered postoperative complications.

Patients were followed-up during the postoperative period according to routine protocols. Patient-controlled analgesia was used to manage postoperative pain until POD 2. Oral analgesics were initiated on POD 3. Sips of water on POD 2 were followed by clear liquids and soft diet on POD 3. Patients were allowed to mobilize on the day of surgery. Blood pressure, pulse rate, body temperature, and hemogram were frequently checked, and CRP levels were measured on POD 1, 3, 5, and 7. Postoperative laboratory test results were obtained by analyzing morning blood samples. The highest body temperature and pulse rate during the day were used as day values.

The prerequisite conditions for safe discharge were the following: 1) able to tolerate oral intake, 2) with generally good condition, and 3) has adequate pain control. A total of 1,438 and 512 patients were selected for the study and validation cohorts, respectively (Fig. 1). We defined an event as the occurrence of grade II or higher complication after POD 3. Patients without an event were considered to have no delayed complications, and those with an event were considered to have delayed complications and were not suitable for discharge on POD 3.

### Statistical analysis
Data are presented as median and 1st–3rd quartiles or mean and standard deviation for continuous variables, and as frequencies and percentages for categorical variables. For comparisons between groups, t-tests or Mann-Whitney tests were used for continuous variables, and \( \chi^2 \) tests or Fisher tests were used for categorical variables.

**Fig. 1.** Flow diagram showing the number of patients who were included in the study and validation cohorts. ASA = American Society of Anesthesiologists.
Important POD 3 variables were selected based on the receiver operating characteristic (ROC) curves. Continuous predictors were dichotomized for further modelling and clinical usability. Youden’s index (sensitivity + specificity – 1) was used to determine the optimal cut-off value of each continuous parameter, and patients were divided into 2 groups: low- and high-risk. To evaluate the prognostic effects of laboratory values on the primary outcome (i.e., the presence of grade II or higher complications after POD 3), we analyzed all clinicopathological variables and important POD 3 variables using logistic regression. In the univariate models, the variables were tested individually. In the multivariate model, all variables were entered into the model. Variables known to be clinically relevant or identified in the multivariate model were entered into a reduced multivariate model. The model with the lowest Akaike information criterion and highest C-statistic was selected as the final model. Results were reported as odds ratios (ORs) with 95% confidence intervals (CIs). The assumptions of the model were verified. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy were used as performance metrics for POD 3 independent variables. Independent variables were evaluated both individually and in combination. When all evaluated variables were at low risk simultaneously, it was defined as a low risk for delayed complications. As we aimed to rule out the presence of complications, we mainly focused on parameters with high NPV, high sensitivity, and low false negative results [23]. Statistical analysis was performed using R software (R version 4.0.4; R Foundation for Statistical Computing, Vienna, Austria) with R packages, including tidyverse, finalfit, rms, cutpointr, and epiR. Statistical significance was defined as a 2-sided P-value of <0.05.

RESULTS

Of the 1,438 patients with gastric cancer in the study cohort, 900 (62.6%) were male and 538 (37.4%) were female. The median patient age was 60 years (range, 51–68 years). From the total cohort, 1,046 (72.7%) patients had stage I cancer, 176 (12.2%) had stage II cancer, and 216 (15%) had stage III cancer. A total of 142 patients (9.9%) experienced delayed grade II or higher complications and were considered unsuitable for safe early discharge. The demographic and clinical characteristics of the patients according to their complication status are presented in Table 1. The daily changes in laboratory values are presented in Supplementary Fig. 1.

Among the POD 3 variables, the ROC curves showed that CRP, body temperature, pulse rate, and neutrophil count had a higher area under curve (Supplementary Fig. 2). Univariate logistic regression analysis of clinicopathological and laboratory variables (age, sex, ASA classification, approach, extent of gastrectomy and lymphadenectomy, combined resection, operation time, intraoperative blood loss, pathological stage, POD 3 factors [body temperature, pulse rate, CRP, and neutrophil count]) were significantly associated with delayed complications (Table 2). In the reduced multivariate model, approach (0.49, 95% CI, 0.32–0.76, P=0.001), extent of gastrectomy (2.42, 95% CI, 1.59–3.67, P<0.001), POD 3 body temperature (3.25, 95% CI, 2.06–5.11, P<0.001), POD 3 pulse rate (2.05, 95% CI, 1.34–3.11, P=0.001), POD 3 CRP (2.07, 95% CI, 1.35–3.19, P=0.001), and POD 3 neutrophil count (2.23, 95% CI, 1.50–3.33; P=0.001) were identified as independent prognostic factors. The relationships between the POD 3 parameters and the probability of delayed complications are shown in Fig. 2. The optimal cut-off values derived from Youden’s index for body temperature, pulse rate, CRP, and neutrophil count were 38°C, 90/min, 110 mg/L, and 6.7×10³ cells, respectively.
The NPV for ruling out delayed grade II or higher complications was 93.1% for temperature alone, 93.2% for pulse alone, 94.8% for CRP alone, and 93.8% for neutrophil count alone (Supplementary Table 1). The sensitivity of these 4 parameters alone ranged from 38.0% to 63.4%. Using the 4-parameter algorithm (when all 4 of these parameters were low risk) across all patients in the study cohort, the NPV was 95.9% (95% CI, 94.2–97.3), sensitivity was 80.3% (95% CI, 72.8–86.5), specificity was 51.1% (95% CI, 48.3–53.8), PPV was 15.2% (95% CI, 12.7–18.0), and the overall accuracy was 54% (95% CI, 51.3–56.6). When the 4-parameter algorithm was tested in various subgroups of patients, the NPV was consistent across subgroups (Table 3).

The false negative rate in the study cohort was 1.9% (28/1,438). The median duration to complications was 5.5 (5–7) days for false negative patients. Among the 28 patients, 4 patients experienced grade II complications, 3 patients experienced grade IIIa complications...

| Variables                      | Study cohort (n=1,438) | Validation cohort (n=512) |
|--------------------------------|------------------------|---------------------------|
|                                | No delayed complications (n=1,296, 90.1%) | No delayed complications (n=462, 90.2%) | P-value |
| Age (yr)                       | 59 (51–68)             | 63 (55.2–72.8)            | <0.001  |
| Sex                            |                        |                           | >0.05   |
| Male                           | 790 (61.0)             | 110 (77.5)                | 278 (60.2) | 26 (52.0) |
| Female                         | 506 (39.0)             | 32 (22.5)                 | 184 (39.8) | 24 (48.0) |
| BMI (kg/m²)                    | 23.5 (21.6–25.8)       | 22.6 (20.6–25.4)          | 0.020   |
| Previous abdominal surgery     | 481 (37.1)             | 57 (40.1)                 | 0.538   |
| ASA                            |                        |                           | >0.05   |
| I                              | 406 (31.3)             | 42 (29.6)                 | 88 (19.0) | 10 (20.0) |
| II                             | 671 (51.8)             | 62 (43.7)                 | 321 (69.5) | 32 (64.0) |
| III                            | 219 (16.9)             | 38 (26.8)                 | 53 (11.5) | 8 (16.0)  |
| Comorbidty                     | 689 (53.2)             | 85 (59.9)                 | 0.153   |
| Approach                       |                        |                           | <0.001  |
| Open                           | 196 (15.1)             | 48 (33.8)                 | 175 (37.9) | 30 (60.0) |
| Laparoscopy                    | 697 (53.8)             | 59 (41.5)                 | 198 (42.9) | 14 (28.0) |
| Robotic                        | 403 (31.1)             | 35 (24.6)                 | 89 (19.3) | 6 (12.0)  |
| Extent of gastrectomy          |                        |                           | <0.001  |
| Subtotal                       | 1,104 (85.2)           | 84 (59.2)                 | 397 (85.9) | 34 (68.0) |
| Total                          | 192 (14.8)             | 58 (40.8)                 | 65 (14.1) | 16 (32.0) |
| Extent of lymphadenectomy      |                        |                           | 0.004   |
| D1+                            | 847 (65.4)             | 75 (52.8)                 | 220 (47.6) | 13 (26.0) |
| D2                             | 449 (34.6)             | 67 (47.2)                 | 242 (52.4) | 37 (74.0) |
| Combined resection             | 131 (10.1)             | 26 (18.3)                 | 27 (5.8)  | 9 (18.0)  |
| Operation time (min)           | 159 (131–198)          | 181 (147.2–236.8)         | 0.001   |
| Intraoperative bleeding (mL)   | 40 (20–79)             | 70 (30–125.2)             | <0.001  |
| T classification               |                        |                           | 0.016   |
| T1                             | 908 (70.1)             | 73 (51.4)                 | 310 (67.1) | 23 (46.0) |
| T2                             | 129 (10.0)             | 15 (10.6)                 | 46 (10.0) | 10 (20.0) |
| T3                             | 125 (9.6)              | 22 (15.5)                 | 54 (11.7) | 7 (14.0)  |
| T4                             | 134 (10.3)             | 32 (22.5)                 | 52 (11.3) | 10 (20.0) |
| N classification               |                        |                           | <0.001  |
| N0                             | 974 (75.2)             | 84 (59.2)                 | 343 (74.2) | 28 (56.0) |
| N1                             | 131 (10.1)             | 21 (14.8)                 | 46 (10.0) | 5 (10.0)  |
| N2                             | 84 (6.5)               | 12 (8.5)                  | 38 (8.2)  | 8 (16.0)  |
| N3                             | 107 (8.3)              | 25 (17.6)                 | 35 (7.6)  | 9 (18.0)  |
| Pathological stage             |                        |                           | <0.001  |
| Stage I                        | 968 (74.7)             | 78 (54.9)                 | 334 (72.3) | 27 (54.0) |
| Stage II                       | 150 (11.6)             | 26 (18.3)                 | 67 (14.5) | 8 (16.0)  |
| Stage III                      | 178 (13.7)             | 38 (26.8)                 | 61 (13.2) | 15 (30.0) |

Data are presented as number (%) or median (1st–3rd quartile).

BMI = body mass index; ASA = American Society of Anesthesiologists.
(2 patients had pleural effusion requiring thoracentesis or pigtail insertion on POD 7 and POD 8, and one patient had biliary injury requiring stenting on POD 7), and one patient experienced a grade IVa complication (esophagojejunostomy leakage managed with

| Variables                      | Univariate | Multivariate | Reduced multivariate |
|--------------------------------|------------|--------------|----------------------|
| Age (yr)                       |            |              |                      |
| ≤60                            | -          | -            | -                    |
| >60                            | 1.47 (1.04–2.09, P=0.030) | 1.17 (0.75–1.81, P=0.493) | 1.21 (0.80–1.86, P=0.369) |
| Sex                            |            |              |                      |
| Male                           | -          | -            | -                    |
| Female                         | 0.45 (0.30–0.68, P<0.001) | 0.67 (0.41–1.05, P=0.087) | 0.71 (0.45–1.11, P=0.146) |
| BMI (kg/m²)                    |            |              |                      |
| ≤27.3                          | -          | -            | -                    |
| >27.3                          | 1.27 (0.77–2.03, P=0.326) | 1.10 (0.62–1.90, P=0.731) | -                    |
| Previous abdominal surgery     |            |              |                      |
| No                             | -          | -            | -                    |
| Yes                            | 1.14 (0.79–1.61, P=0.479) | 1.41 (0.93–2.12, P=0.107) | -                    |
| ASA                            |            |              |                      |
| I                              | -          | -            | -                    |
| II                             | 0.89 (0.59–1.35, P=0.590) | 0.71 (0.44–1.16, P=0.171) | 0.70 (0.44–1.12, P=0.137) |
| III                            | 1.68 (1.05–2.68, P=0.031) | 0.97 (0.51–1.83, P=0.934) | 0.97 (0.54–1.72, P=0.922) |
| Comorbidity                    |            |              |                      |
| No                             | -          | -            | -                    |
| Yes                            | 1.31 (0.93–1.88, P=0.130) | 0.97 (0.62–1.54, P=0.911) | -                    |
| Approach                       |            |              |                      |
| Open                           | -          | -            | -                    |
| MIS                            | 0.35 (0.24–0.51, P=0.001) | 0.50 (0.29–0.87, P=0.013) | 0.49 (0.32–0.76, P=0.001) |
| Extent of gastrectomy          |            |              |                      |
| Subtotal                       | -          | -            | -                    |
| Total                          | 3.97 (2.74–5.73, P<0.001) | 2.08 (1.31–3.29, P=0.002) | 2.42 (1.59–3.67, P=0.001) |
| Extent of lymphadenectomy       |            |              |                      |
| D1+                            | -          | -            | -                    |
| D2                             | 1.69 (1.19–2.39, P=0.003) | 0.81 (0.50–1.29, P=0.376) | -                    |
| Combined resection             |            |              |                      |
| No                             | -          | -            | -                    |
| Yes                            | 1.99 (1.23–3.12, P=0.003) | 1.08 (0.60–1.87, P=0.797) | -                    |
| Operation time (min)           |            |              |                      |
| ≤210                           | -          | -            | -                    |
| >210                           | 2.89 (2.01–4.14, P=0.001) | 1.32 (0.82–2.11, P=0.252) | -                    |
| Intraoperative bleeding (mL)   |            |              |                      |
| ≤70                            | -          | -            | -                    |
| ≥70                            | 2.48 (1.75–3.53, P=0.001) | 1.01 (0.63–1.61, P=0.971) | -                    |
| Pathological stage             |            |              |                      |
| Stage I                        | -          | -            | -                    |
| Stage II                       | 2.15 (1.32–3.42, P=0.002) | 1.43 (0.78–2.58, P=0.236) | -                    |
| Stage III                      | 2.65 (1.73–4.01, P<0.001) | 1.47 (0.79–2.70, P=0.220) | -                    |
| Body temperature (POD 3, °C)   |            |              |                      |
| ≤38                            | -          | -            | -                    |
| >38                            | 6.75 (4.55–9.97, P<0.001) | 3.17 (1.99–5.02, P<0.001) | 3.25 (2.06–5.11, P<0.001) |
| Pulse (POD 3, /min)            |            |              |                      |
| ≤90                            | -          | -            | -                    |
| >90                            | 3.85 (2.68–5.51, P=0.001) | 1.96 (1.28–2.99, P=0.002) | 2.05 (1.34–3.11, P=0.001) |
| CRP (POD 3, mg/L)              |            |              |                      |
| ≤110                           | -          | -            | -                    |
| >110                           | 4.71 (3.29–6.81, P<0.001) | 2.03 (1.31–3.16, P=0.002) | 2.07 (1.35–3.19, P=0.001) |
| Neutrophil count (POD 3)       |            |              |                      |
| ≤6.7×10⁹ cells                 | -          | -            | -                    |
| >6.7×10⁹ cells                 | 3.83 (2.69–5.47, P=0.001) | 2.21 (1.48–3.31, P=0.001) | 2.23 (1.50–3.33, P=0.001) |

The first row of each variable represents the reference level. Data are presented as odds ratio, 95% confidence interval, and P-value. BMI = body mass index; ASA = American Society of Anesthesiologists; MIS = minimally invasive surgery; CRP = C-reactive protein; POD = postoperative day.

https://doi.org/10.5230/jgc.2022.22.e32
conservative Levin tube drainage procedures and intensive care unit management on POD 7). The patient with biliary injury had no symptoms, except for a bilious color change of abdominal drainage and elevated serum bilirubin on POD 3. The patient with leakage had a history of hypertension, stroke, abdominal aortic aneurysm with stenting, brain tumor, and lung emphysema. No 90-day mortality rate was observed.

The 4-parameter algorithm was tested on a separate validation dataset (Fig. 1, Table 1), with a sensitivity of 66%, specificity of 54.5%, PPV of 13.6%, and NPV of 93.7%. When tested in various subgroups of patients, the NPV was consistent across subgroups, except for approach (Table 3).

The false negative rate in the validation cohort was 3.3% (17/512). The median duration to delayed complications was 9 (5–13) days for false negative patients. Among these 17 patients, 12 experienced grade II complications, 4 experienced grade IIIa complications, and one experienced grade V complications. The first patient with grade IIIa complication was discharged on POD 5 without an event, but after 5 days, the patient experienced delayed complications.
abrupt epigastric pain and visited the emergency department. An imaging study detected a hematoma around the gastroduodenal artery, and the patient underwent embolization procedure on POD 12. The second patient with grade IIIa complications underwent pigtail drainage for pneumoperitoneum, which was found on POD 13. The third patient underwent liver abscess drainage on POD 13, and the fourth patient underwent endoscopic stenting on POD 13 for the oedematous anastomosis site after gastroduodenostomy. The patient who experienced a grade V complication was a 91-year-old woman with a urinary tract infection on POD 6 who was treated with antibiotics and discharged on POD 13. One week after discharge, the patient visited the outpatient department as scheduled and booked the next visit for 2 months. No signs of infection were observed. One week later, the patient presented with urinary sepsis and died the next day (POD 27). Fig. 3 shows the timing and grade of delayed complications among false negative patients in the study and validation cohorts.

DISCUSSION

We investigated the relationship between POD 3 parameters and delayed complication status among patients undergoing curative gastrectomy for gastric cancer and found that CRP level, body temperature, pulse rate, and neutrophil count were the most important independent predictors. When patients were classified as low- or high-risk according to these 4 parameters, the NPV was 95.9% among patients in whom all 4 parameters were low risk. Only 28 of 1,438 patients were classified as false negatives in the study cohort, and the

Safe Discharge Criteria After Gastrectomy

Table 3. Performance metrics of 4-parameter algorithm in patient subgroups in the study and validation cohorts

| Variables                  | Number | Delayed complications (%) | TP   | FP   | FN   | TN   | Prevalence (%) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) |
|----------------------------|--------|---------------------------|------|------|------|------|----------------|----------------|----------------|---------|---------|---------------|
| All patients               | 1,438  | 9.9                       | 114  | 634  | 28   | 662  | 52.0           | 80.3           | 51.1           | 15.2    | 95.9    | 54.0          |
|                           | 512    | 9.8                       | 33   | 210  | 17   | 252  | 47.5           | 66.0           | 54.5           | 13.6    | 93.7    | 55.7          |
| ASA                       |        |                           |      |      |      |      |                |                |                |         |         |               |
| ASA I/II                   | 1,181  | 8.8                       | 81   | 520  | 23   | 557  | 50.9           | 77.9           | 51.7           | 13.5    | 96.0    | 54.0          |
|                           | 451    | 9.3                       | 27   | 174  | 15   | 235  | 44.6           | 64.3           | 57.5           | 13.4    | 94.0    | 58.1          |
| ASA III                    | 257    | 14.8                      | 33   | 114  | 5    | 105  | 57.2           | 86.8           | 47.9           | 22.4    | 95.5    | 53.7          |
|                           | 61     | 13.1                      | 6    | 36   | 2    | 17   | 68.9           | 75.0           | 32.1           | 14.3    | 89.5    | 37.7          |
| Sex                       |        |                           |      |      |      |      |                |                |                |         |         |               |
| Female                     | 538    | 5.9                       | 22   | 210  | 10   | 296  | 43.1           | 68.8           | 58.5           | 9.5     | 96.7    | 59.1          |
|                           | 208    | 11.5                      | 13   | 75   | 11   | 109  | 42.3           | 54.2           | 59.2           | 14.8    | 90.8    | 58.7          |
| Male                       | 900    | 12.2                      | 92   | 424  | 18   | 366  | 57.3           | 83.6           | 46.3           | 17.8    | 95.3    | 50.9          |
|                           | 304    | 8.6                       | 20   | 135  | 6    | 143  | 51.0           | 76.9           | 51.4           | 12.9    | 96.0    | 53.6          |
| Approach                   |        |                           |      |      |      |      |                |                |                |         |         |               |
| MIS                        | 1,194  | 7.9                       | 72   | 515  | 22   | 585  | 49.2           | 76.6           | 53.2           | 12.3    | 96.4    | 55.0          |
|                           | 307    | 6.5                       | 16   | 115  | 4    | 172  | 42.7           | 80.0           | 59.9           | 12.2    | 97.7    | 61.2          |
| Open                       | 244    | 19.7                      | 42   | 119  | 6    | 77   | 66.0           | 87.5           | 39.3           | 26.1    | 92.8    | 48.8          |
|                           | 205    | 14.6                      | 17   | 95   | 13   | 80   | 54.6           | 56.7           | 45.7           | 15.2    | 86.0    | 47.3          |
| Pathological stage         |        |                           |      |      |      |      |                |                |                |         |         |               |
| Stage I                    | 1,046  | 7.5                       | 59   | 449  | 19   | 519  | 48.6           | 75.6           | 53.6           | 11.6    | 96.5    | 55.3          |
|                           | 361    | 7.5                       | 17   | 135  | 10   | 199  | 42.1           | 63.0           | 59.6           | 11.2    | 95.2    | 59.8          |
| Stage II/III               | 392    | 16.3                      | 55   | 185  | 9    | 143  | 61.2           | 85.9           | 43.6           | 22.9    | 94.1    | 50.5          |
|                           | 151    | 15.2                      | 16   | 75   | 7    | 53   | 60.3           | 69.6           | 41.4           | 17.6    | 88.3    | 45.7          |
| Extent of gastrectomy      |        |                           |      |      |      |      |                |                |                |         |         |               |
| Subtotal                   | 1,188  | 7.1                       | 64   | 556  | 20   | 578  | 49.7           | 76.2           | 52.4           | 10.8    | 96.7    | 54.0          |
|                           | 431    | 7.9                       | 19   | 174  | 15   | 223  | 44.8           | 55.9           | 56.2           | 9.8     | 93.7    | 56.1          |
| Total                      | 250    | 23.2                      | 50   | 108  | 8    | 84   | 63.2           | 86.2           | 43.8           | 31.6    | 91.3    | 53.6          |
|                           | 81     | 19.8                      | 14   | 36   | 2    | 29   | 61.7           | 87.5           | 44.6           | 28.0    | 93.5    | 53.1          |

TP = true positive; FP = false positive; FN = false negative; TN = true negative; PPV = positive predictive value; NPV = negative predictive value; ASA = American Society of Anesthesiologists; MIS = minimally invasive surgery.

*The top row of each item means number of study cohort and the bottom row means number of validation cohort.
Our goal was to develop a simple algorithm consisting of routine follow-up parameters obtained on POD 3 that could be used to predict whether complications requiring treatment would arise within the first postoperative month. A previous study employed a similar approach to predict complications and make safe discharge decisions using the parameters of age, approach, presence of combined resection, POD 5-to-preoperative white blood cell ratio, CRP level on POD 5, and body temperature on POD 4 [18]. For the previous algorithm, the sensitivity was 96.7% and the NPV was 75.5%, which were higher and lower, respectively, than the values obtained in the present study. Another previous study used a 7-parameter nomogram to predict severe postoperative complications among patients who underwent gastrectomy, which included sex, body temperature, amount of oral intake and ambulatory duration on POD 4, pain score, and proportion of neutrophils and defecation status on POD 5 [17]. The NPV was 95.7% for the development dataset and 91.6% for the validation dataset. Although both algorithms appear to be useful and effective, predicting complications on POD 5 has a low value for clinical application, and the algorithms employ too many parameters to be routinely used in daily clinical practice. In addition, a study that examined only procalcitonin measured on POD 3 had a 97.6% NPV and 75% sensitivity in ruling out intra-abdominal infections after gastric cancer surgery [14]. Although procalcitonin is a useful marker for diagnosing bacterial and fungal infections, its lower validity for predicting non-infective complications restricts its use as a safe discharge marker.

We found that body temperature, pulse rate, CRP level, and neutrophil count were independent predictors of delayed postoperative complications. All 4 parameters are related to systemic inflammatory response and may reflect different aspects of this response. However, higher levels of these variables are often observed in the very early PODs in patients without complications. Previous studies have sought to determine differences in postoperative parameters between patients with and without complications. CRP on POD 3 and POD 4 show the highest diagnostic accuracy [13,24,25]. Thus, we arbitrarily chose POD 3 during the hypothesis development phase because this day is after the point after which values are initially high during the early postoperative period, but are early enough to reduce...
the length of hospital stay and its associated cost. Vital signs such as body temperature, pulse rate, and markers reflecting the inflammatory response have been frequently investigated [3,11,26,27]. The present study shows that all 4 independent parameters can be used alone based on the NPV. However, combinations of 3 or 4 parameters increased the algorithm sensitivity and decreased the number of false negative results. It should be kept in mind that the purpose of the proposed algorithm is to predict patients who will not have delayed complications; therefore, all performance metrics should be interpreted in this context.

The oral intake status and the general condition of the patient were not included in the algorithm because both are mandatory components for safe early discharge, and they were not used as exclusion criteria because both are signs of complications. It is difficult to evaluate the effect of these 2 parameters on the safe early discharge decision in a retrospective study; however, oral intake status, general condition, and even the patient’s willingness to be discharged should be considered prerequisites for applying the proposed safe early discharge criteria.

The outcome measure in the present study was grade II or higher on POD 3. It would also be possible to use grade III or higher (i.e., major) complications. However, because all grade II complications may require specific treatment, such as intravenous antibiotics or parenteral nutrition, we used delayed grade II or higher complications as an outcome measure because they captured all possible unplanned readmissions to the hospital. Our study showed that most patients who were classified as false negative were readmitted to the hospital a week after discharge, largely due to grade II complications. This finding can be used to improve the standardization of home care and to implement closer follow-up programs in the first week for patients who are discharged early.

When developing algorithms for decision-making, care should be taken when selecting cut-off values. We chose cut-offs that maximized the sum of the sensitivity and specificity. The selected optimal cut-off values for temperature and pulse rate were 38°C and 90/min, respectively, which are the same as those used to define systemic inflammatory response syndrome [28]. However, there are several published thresholds for laboratory values of CRP [16]. We identified 110 mg/L as the threshold value for CRP, which is slightly below the cut-off values described in previous studies, possibly because of the high proportion of patients in our cohort who underwent minimally invasive surgery. Therefore, additional thresholds should be examined in future studies.

The main limitation of the present study is its retrospective design. Although we used a prospective, well-organized database, our study was designed based on the hypothetical assumption that the patients were discharged on POD 3. However, the median length of hospital stay was actually 6 (5–7) days. Therefore, we used detailed complication data to reduce the likelihood of potential misinterpretation. Another limitation is that the data reflected the outcomes of a single experienced surgeon from a tertiary, high-volume center. Some site-specific characteristics, including a high proportion of patients with early gastric cancer and frequent use of minimally invasive surgery, may limit the generalizability of the findings. In addition, because of the known relationship between the prevalence of the outcome and NPV/PPV, some performance metrics should be cautiously evaluated. Although we examined the success of the proposed algorithm using an external validation dataset, further validation of this algorithm in centers with distinct patient populations and other characteristics is critically important. The presented algorithm has been shown to have
varying performances in patient subgroups. To avoid reducing the simplicity of the decision-making process, separate pathways have not been tested for each subgroup but may be considered for different subgroups in future studies.

In conclusion, simple clinical and laboratory parameters, including CRP, body temperature, pulse rate, and neutrophil count obtained on POD 3 can be used in the decision-making process for safe early discharge of post-gastrectomy patients with gastric cancer. The combination of these 4 parameters yielded an NPV of 95.9% in the study dataset and 93.7% in the validation dataset.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Performance metrics of individual and combined versions of postoperative day 3 parameters for the study cohort (n=1,438, complication rate 9.9%)

Click here to view

Supplementary Fig. 1
Daily changes in postoperative parameters according to complication status. Points represent median values and error bars represent 1st–3rd quartiles. Because some parameters are not routinely checked on postoperative day 2, these are blank for some parameters.

Click here to view

Supplementary Fig. 2
Receiver operating characteristic curves of postoperative day 3 parameters for delayed grade II or higher complications. The numbers in parentheses represent the area under the curve values for each parameter.

Click here to view

REFERENCES

1. Shannon AB, Straker RJ 3rd, Fraker DL, Roses RE, Miura JT, Karakousis GC. Ninety-day mortality after total gastrectomy for gastric cancer. Surgery 2021;170:603-609.
2. Tian Y, Cao S, Liu X, Li L, He Q, Jiang L, et al. Randomized controlled trial comparing the short-term outcomes of enhanced recovery after surgery and conventional care in laparoscopic distal gastrectomy (GISSG1901). Ann Surg 2022;275:e15-e21.
3. Guner A, Kim HL. Biomarkers for evaluating the inflammation status in patients with cancer. J Gastric Cancer 2019;19:254-277.
4. Information Committee of the Korean Gastric Cancer Association. Korean Gastric Cancer Association-led nationwide survey on surgically treated gastric cancers in 2019. J Gastric Cancer 2021;21:221-235.
5. Park SH, Kang MJ, Yun EH, Jung KW. Epidemiology of gastric cancer in Korea: trends in incidence and survival based on Korea Central Cancer Registry data (1999-2019). J Gastric Cancer 2022;22:160-168.
6. Weindelmayer J, Mengardo V, Gasparini A, Sacco M, Torroni L, Carlini M, et al. Enhanced recovery after surgery can improve patient outcomes and reduce hospital cost of gastrectomy for cancer in the west: a propensity-score-based analysis. Ann Surg Oncol 2021;28:7087-7094.

7. Roh CK, Son SY, Lee SY, Hur H, Han SU. Clinical pathway for enhanced recovery after surgery for gastric cancer: a prospective single-center phase II clinical trial for safety and efficacy. J Surg Oncol 2020;121:662-669.

8. Zhao J, Hu J, Jiang Z, Wang G, Liu J, Wang H, et al. Outcome of discharge within 72 hours of robotic gastrectomy using enhanced recovery after surgery programs. J Laparoendosc Adv Surg Tech A 2018;28:1279-1286.

9. Roh CK, Choi S, Seo WJ, Cho M, Choi YY, Son T, et al. Comparison of surgical outcomes between integrated robotic and conventional laparoscopic surgery for distal gastrectomy: a propensity score matching analysis. Sci Rep 2020;10:485.

10. Viyuela García C, Medina Fernández FJ, Arjona-Sánchez A, Casado-Adam Á, Sánchez Hidalgo JM, Ruián Peña S, et al. Systemic inflammatory markers for the detection of infectious complications and safe discharge after cytoreductive surgery and HIPEC. Surg Oncol 2020;34:163-167.

11. Tavernier C, Flaris AN, Passot G, Gleen O, Kepenekian V, Cotte E. Assessing criteria for a safe early discharge after laparoscopic colorectal surgery. JAMA Surg 2022;157:52-58.

12. Lee YM, Cho JY, Sung TY, Kim TY, Chung KW, Hong SJ, et al. Clinicopathological risk factors and biochemical predictors of safe discharge after total thyroidectomy and central compartment node dissection for thyroid cancer: a prospective study. Int J Endocrinol 2015;2015:214525.

13. van Winsen M, McSorley ST, McLeod R, MacDonald A, Forshaw MJ, Shaw M, et al. Postoperative C-reactive protein concentrations to predict infective complications following gastrectomy for cancer. J Surg Oncol 2021;124:1060-1069.

14. Yang W, Chen X, Zhang P, Li C, Liu W, Wang Z, et al. Procalcitonin as an early predictor of intra-abdominal infections following gastric cancer resection. J Surg Res 2021;258:352-361.

15. Yeung DE, Peterknecht E, Hajibandeh S, Hajibandeh S, Torrance AW. C-reactive protein can predict anastomotic leak in colorectal surgery: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:1147-1162.

16. Dutta S, Fullarton GM, Forshaw MJ, Horgan PG, McMillan DC. Persistent elevation of C-reactive protein following esophagogastric cancer resection as a predictor of postoperative surgical site infectious complications. World J Surg 2011;35:1017-1025.

17. Yu D, Wu X, Li X, Liu X, Jiang K, Zhao Q, et al. Development and external validation of safe discharge criteria after radical gastrectomy. Cancer Manag Res 2021;13:5251-5261.

18. Park JH, Son YG, Kim TH, Huh YJ, Yang JY, Suh YJ, et al. Identification of candidates for early discharge after gastrectomy. Ann Surg Oncol 2017;24:159-166.

19. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. Cham: Springer International Publishing; 2017.

20. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48.

21. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1-21.

22. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187-196.

https://doi.org/10.5230/jgc.2022.22.e32
23. Korevaar DA, Gopalakrishna G, Cohen JF, Bossuyt PM. Targeted test evaluation: a framework for designing diagnostic accuracy studies with clear study hypotheses. Diagn Progn Res 2019;3:22.
PUBMED | CROSSREF

24. Kørner H, Nielsen HJ, Søreide IA, Nedrebø BS, Søreide K, Knapp JC. Diagnostic accuracy of C-reactive protein for intraabdominal infections after colorectal resections. J Gastrointest Surg 2009;13:1599-1606.
PUBMED | CROSSREF

25. Welsch T, Müller SA, Ulrich A, Kischlat A, Hinz U, Kienle P, et al. C-reactive protein as early predictor for infectious postoperative complications in rectal surgery. Int J Colorectal Dis 2007;22:1499-1507.
PUBMED | CROSSREF

26. Guner A, Kim SY, Yu JE, Min IK, Roh YH, Roh C, et al. Parameters for predicting surgical outcomes for gastric cancer patients: simple is better than complex. Ann Surg Oncol 2018;25:3239-3247.
PUBMED | CROSSREF

27. Guner A, Cho M, Kim YM, Cheong JH, Hyung WJ, Kim HL. Prognostic value of postoperative neutrophil and albumin: reassessment one month after gastric cancer surgery. Front Oncol 2021;11:633924.
PUBMED | CROSSREF

28. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:762-774.
PUBMED | CROSSREF